Halberd (Halberd) Pretax Margin % : -15,133.33% (As of Jul. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Halberd Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Halberd's Pre-Tax Income for the six months ended in Jul. 2023 was $-0.45 Mil. Halberd's Revenue for the six months ended in Jul. 2023 was $0.00 Mil. Therefore, Halberd's pretax margin for the quarter that ended in Jul. 2023 was -15,133.33%.

The historical rank and industry rank for Halberd's Pretax Margin % or its related term are showing as below:

HALB' s Pretax Margin % Range Over the Past 10 Years
Min: -20312.5 Med: -15133.33 Max: -757.14
Current: -15133.33

HALB's Pretax Margin % is ranked worse than
93.22% of 1018 companies
in the Biotechnology industry
Industry Median: -154.275 vs HALB: -15133.33

Halberd Pretax Margin % Historical Data

The historical data trend for Halberd's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd Pretax Margin % Chart

Halberd Annual Data

Trend

Jul08

Jul22

Jul23

Pretax Margin %

-757.14

-20,312.50

-15,133.33

Halberd Semi-Annual Data
	Jul08	Jul22	Jul23
Pretax Margin %	-757.14	-20,312.50	-15,133.33

Competitive Comparison of Halberd's Pretax Margin %

For the Biotechnology subindustry, Halberd's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Halberd's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halberd's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Halberd's Pretax Margin % falls into.

Halberd Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Halberd's Pretax Margin for the fiscal year that ended in Jul. 2023 is calculated as

Pretax Margin	=	Pre-Tax Income (A: Jul. 2023 )	/	Revenue (A: Jul. 2023 )
	=	-0.454	/	0.003
	=	-15,133.33 %

Halberd's Pretax Margin for the quarter that ended in Jul. 2023 is calculated as

Pretax Margin	=	Pre-Tax Income (Q: Jul. 2023 )	/	Revenue (Q: Jul. 2023 )
	=	-0.454	/	0.003
	=	-15,133.33 %

Halberd (OTCPK:HALB) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

Halberd Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Halberd's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Halberd (Halberd) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Pretax Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 25, Jackson Center, PA, USA, 16133

Website

https://www.halberdcorporation.com

Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.

Executives

John Christopher Maddox	director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO	10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist	director, 10 percent owner, officer: CEO, Secretary and Director	24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr.	director	50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas	director	280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236